Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Stoke Therapeutics
ISIN US86150R1077
|WKN A2PLTL
Market cap (in EUR)
1,687 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 1,687 m |
| EPS, EUR | -0.13 |
| P/B ratio | 5.5 |
| P/E ratio | 50.3 |
| Dividend yield | 0.00% |
Income statement (2025)
| Revenue, EUR | 163 m |
| Net income, EUR | -6 m |
| Profit margin | -3.73% |
What ETF is Stoke Therapeutics in?
There are 2 ETFs which contain Stoke Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Stoke Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.13% | Equity United States Health Care Biotech | 48 |
| JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) | 0.02% | Equity United States Small Cap | 189 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.